Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa

Purpose of reviewThis review provides an update of recent data on the development of HIV-1 drug resistance during treatment and its transmission in sub-Saharan Africa after the scale-up of antiretroviral therapy (ART). Recent findingsEvidence is accumulating of a rising prevalence of transmitted HIV drug resistance (TDR), predominantly associated with nonnucleoside reverse transcriptase inhibitors (NNRTIs), in east and southern Africa. Pretherapy resistance is associated with first-line therapy failure. Accumulation of resistance mutations during first-line failure can be prevented by early detection and timely switching to second-line ART. Important gaps in service delivery and programme performance, associated with resistance development, affect a considerable proportion of ART programmes, particularly with respect to inadequate supply systems and patient retention. The reduction in new HIV infections associated with earlier use of ART is predicted to outweigh the risk of increasing TDR. Future levels of TDR are estimated to be diminished by improving switching practices to second-line regimens. SummaryTDR is on the rise after the recent scale-up of ART in Africa. To prevent the development and spread of drug resistance and sustain the effectiveness of ART programmes, there is a need to improve drug supply systems, patient retention and access to routine viral load monitoring. Enhanced resistance monitoring is warranted in Africa.

[1]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[2]  C. Rouzioux,et al.  Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naive Children: Rare Protease Inhibitor Resistance Mutations But High Lamivudine/Emtricitabine Resistance at the Time of Virologic Failure , 2011, The Pediatric infectious disease journal.

[3]  U. Unicef,et al.  Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. , 2011 .

[4]  R. Kantor,et al.  Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  L. Morris,et al.  Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. , 2011, AIDS research and human retroviruses.

[6]  T. R. D. de Wit,et al.  HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. , 2011, The Lancet. Infectious diseases.

[7]  D. Bennett,et al.  HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  W. Stevens,et al.  Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. , 2012, AIDS research and human retroviruses.

[9]  N. Parkin,et al.  Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Pillay,et al.  Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.

[11]  M. Hughes,et al.  Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. , 2012, The New England journal of medicine.

[12]  M. Kozal,et al.  Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure , 2012, AIDS.

[13]  L. Mofenson,et al.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) , 2001, AIDS.

[14]  David P. Wilson,et al.  Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings , 2011, AIDS.

[15]  D. Bennett,et al.  Darunavir: pharmacokinetics and drug interactions. , 2008 .

[16]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[17]  D. Bennett,et al.  World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites , 2008, Antiviral therapy.

[18]  M. Wainberg,et al.  Template Usage Is Responsible for the Preferential Acquisition of the K65R Reverse Transcriptase Mutation in Subtype C Variants of Human Immunodeficiency Virus Type 1 , 2008, Journal of Virology.

[19]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[20]  M. Wainberg,et al.  Development of antiretroviral drug resistance. , 2011, The New England journal of medicine.

[21]  A. Crook,et al.  Evaluating the extent of potential resistance to pre‐exposure prophylaxis within the UK HIV‐1‐infectious population of men who have sex with men , 2012, HIV medicine.

[22]  Arthur W. Wetzel,et al.  Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP) , 2011, PloS one.

[23]  Kishor Mandaliya,et al.  HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. , 2011, The Lancet. Infectious diseases.

[24]  K. Freedberg,et al.  Impact of Drug Stock-Outs on Death and Retention to Care among HIV-Infected Patients on Combination Antiretroviral Therapy in Abidjan, Côte d'Ivoire , 2010, PloS one.

[25]  K. Metzner,et al.  Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure , 2011 .

[26]  T. R. D. Wit,et al.  Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis , 2012, AIDS.

[27]  B. Simen,et al.  Use of Dried-Blood-Spot Samples and In-House Assays To Identify Antiretroviral Drug Resistance in HIV-Infected Children in Resource-Constrained Settings , 2011, Journal of Clinical Microbiology.

[28]  D. Katzenstein,et al.  Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings , 2012, AIDS.

[29]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[30]  Wolfgang Preiser,et al.  Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI‐based regimens in the western cape, South Africa , 2011, Journal of medical virology.

[31]  N. Ford,et al.  Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis , 2012, AIDS.

[32]  M. Wainberg,et al.  Factors Affecting Template Usage in the Development of K65R Resistance in Subtype C Variants of HIV Type-1 , 2010, Antiviral chemistry & chemotherapy.

[33]  R. Wood,et al.  Low Rates of Nucleoside Reverse Transcriptase Inhibitor Resistance in a Well-Monitored Cohort in South Africa on Antiretroviral Therapy , 2011, Antiviral therapy.

[34]  A. Wensing,et al.  Long-term Outcome of Children Receiving Antiretroviral Treatment in Rural South Africa: Substantial Virologic Failure on First-line Treatment , 2011, The Pediatric infectious disease journal.

[35]  G. V. Van Zyl,et al.  It is time to consider third-line options in antiretroviral-experienced paediatric patients? , 2011, Journal of the International AIDS Society.

[36]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[37]  B. Hirschel,et al.  A Randomized Comparison of Second-Line Lopinavir/ Ritonavir Monotherapy versus Tenofovir/Lamivudine/ Lopinavir/Ritonavir in Patients Failing Nnrti Regimens: The HIV Star Study , 2012, Antiviral therapy.

[38]  G. V. Van Zyl,et al.  PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE , 2009, The Pediatric infectious disease journal.

[39]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[40]  T. F. Rinke de Wit,et al.  Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.

[41]  J. Mellors,et al.  HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  V. Colizzi,et al.  Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon , 2011, The Pediatric infectious disease journal.

[43]  C. Bositis,et al.  Updates to the World Health Organization's Recommendations for the Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. , 2010, Medical journal of Zambia.

[44]  Ingrid A. Beck,et al.  Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine. , 2012, The Journal of infectious diseases.

[45]  J. Montaner,et al.  Time to get serious about HIV antiretroviral resistance. , 2011, The Lancet. Infectious diseases.

[46]  David Dunn,et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.

[47]  T. F. Rinke de Wit,et al.  Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. , 2012, The Journal of infectious diseases.

[48]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[49]  Christian Laurent,et al.  Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients , 2011, AIDS.

[50]  T. F. Rinke de Wit,et al.  Short communication: High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. , 2012, AIDS research and human retroviruses.

[51]  M. Cotton,et al.  Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. , 2012, The Cochrane database of systematic reviews.

[52]  M. Peeters,et al.  Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  A. Wensing,et al.  Accumulation of Drug Resistance and Loss of Therapeutic Options Precede Commonly Used Criteria for Treatment Failure in HIV-1 Subtype-C-Infected Patients , 2012, Antiviral therapy.

[54]  W. Moss,et al.  Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. , 2008, The Lancet. Infectious diseases.

[55]  F. Wit,et al.  Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.

[56]  D. Bennett,et al.  The World Health Organization's global strategy for prevention and assessment of HIV drug resistance , 2008, Antiviral therapy.

[57]  Sally Blower,et al.  Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance , 2011, Scientific reports.

[58]  S. Hammer,et al.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. , 2004, The New England journal of medicine.

[59]  Ian Sanne,et al.  Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.

[60]  S. Rosen,et al.  The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data , 2011, Journal of the International AIDS Society.

[61]  L. Morris,et al.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine , 2011, AIDS.

[62]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[63]  D. Pillay,et al.  Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings , 2011, AIDS.

[64]  P. Ghys,et al.  Global trends in molecular epidemiology of HIV-1 during 2000–2007 , 2011, AIDS.

[65]  I. Vincenzi Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. , 2011 .

[66]  L. Mofenson,et al.  Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. , 2012, The New England journal of medicine.

[67]  N. Parkin,et al.  Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  T. F. Rinke de Wit,et al.  Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  T. F. Rinke de Wit,et al.  Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala , 2011, AIDS.

[70]  G. Maartens,et al.  Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. , 2008, JAMA.

[71]  N. Rollins,et al.  Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  Lei Wang,et al.  Prevention of HIV-1 infection with early antiretroviral therapy. , 2011, The New England journal of medicine.

[73]  J. Eron,et al.  Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline * , 2010, HIV medicine.

[74]  A. Puren,et al.  Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.